Drug
Floretyrosine F 18
Floretyrosine F 18: highest development phase Phase 3, developed by Telix Pharmaceuticals (Innovations) Pty Limited. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Telix Pharmaceuticals (Innovations) Pty Limited
Trials
| Drug | Phase | Indication |
|---|---|---|
| Floretyrosine F 18 ([18F]FET) NCT07931261 | Phase 3 | Brain Metastasis |
Latest
No recent events.
Follow Floretyrosine F 18 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.